ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.439,78
0,83%
S&P 500
5.464,62
-0,16%
US Dollar vs BRL
5,4416
-0,23%
Bitcoin
64.219,90
-0,93%
Brent Oil
84,45
-0,65%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Leap Therapeutics Inc (LPTX)

  7. Leap Therapeutics Inc (LPTX) Notícias

LPTX

Leap Therapeutics (LPTX)

Leap Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LPTX
DataHoraFonteTítuloCódigoCompanhia
24/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
23/05/202417:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LPTXLeap Therapeutics Inc
13/05/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
13/05/202408:00PR Newswire (US)Leap Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
13/05/202407:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPTXLeap Therapeutics Inc
10/05/202418:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPTXLeap Therapeutics Inc
11/04/202409:30PR Newswire (US)Leap Therapeutics Announces $40 Million Private PlacementNASDAQ:LPTXLeap Therapeutics Inc
18/03/202408:00PR Newswire (US)Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
31/01/202423:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
26/01/202419:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LPTXLeap Therapeutics Inc
16/01/202419:05PR Newswire (US)Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
03/01/202409:00PR Newswire (US)Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
02/01/202409:00PR Newswire (US)Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
11/12/202318:05PR Newswire (US)Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
21/11/202309:00PR Newswire (US)Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
13/11/202309:00PR Newswire (US)Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
05/09/202308:00PR Newswire (US)Leap Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:LPTXLeap Therapeutics Inc
14/08/202308:00PR Newswire (US)Leap Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
12/07/202308:00PR Newswire (US)Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
20/06/202313:30PR Newswire (US)Leap Therapeutics Announces Reverse Stock SplitNASDAQ:LPTXLeap Therapeutics Inc
15/06/202307:26Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LPTXLeap Therapeutics Inc
14/06/202317:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LPTXLeap Therapeutics Inc
09/06/202317:11Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202318:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202318:10PR Newswire (US)Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingNASDAQ:LPTXLeap Therapeutics Inc
15/05/202308:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LPTXLeap Therapeutics Inc
15/05/202308:00PR Newswire (US)Leap Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
28/04/202317:23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LPTXLeap Therapeutics Inc
28/04/202317:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LPTXLeap Therapeutics Inc
21/04/202318:13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LPTXLeap Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LPTX

Seu Histórico Recente

BOV
HAGA3
HAGA ON
BOV
IBOV
Índice Bovespa
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
TELB4
TELEBRAS PN
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
IFCM3
Infracommerce Caxaas ON
BOV
SAPR4
SANEPAR PN
BOV
ZAMP3
Zamp ON
BOV
GOLL4
GOL PN
BOV
IDIV
Dividend
BOV
DASA3
DASA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados